妊娠耐多药结核病化学治疗进展

doi:10.3969/j.issn.1000-6621.2014.02.009

中国防痨杂志 ›› 2014, Vol. 36 ›› Issue (2): 126-130.doi: 10.3969/j.issn.1000-6621.2014.02.009

妊娠耐多药结核病化学治疗进展

韩丹段琼红陈梓周美兰陆兰英阮汉利

430030 武汉市结核病防治所医务科（韩丹），人教科（段琼红），全球基金项目办公室（陈梓、周美兰），耐多药肺结核病房（陆兰英），肺结核合并肺部肿瘤病房（阮汉利）

收稿日期:2013-06-09 出版日期:2014-02-10 发布日期:2014-04-10
通信作者: 陆兰英；阮汉利 E-mail:lly2006oy@126.com；317376480@qq.com

Progress in chemotherapy of MDR-TB during pregnancy

HAN Dan, DUAN Qiong-hong, CHEN Zi, ZHOU Mei-lan, LU Lan-ying, RUAN Han-li

Office of Medical Services Wuhan TB Control Center，Wuhan 430030，China

Received:2013-06-09 Online:2014-02-10 Published:2014-04-10
Contact: LU Lan-ying；RUAN Han-li E-mail:lly2006oy@126.com；317376480@qq.com

摘要/Abstract

摘要： 妊娠耐多药结核病的治疗是临床上较为棘手的问题，目前国内外没有统一的方案。笔者对妊娠耐多药结核病的流行病学情况、治疗药物和化疗方案等进展情况进行了综述，为妊娠耐多药结核病患者的治疗提供了一定的参考。

关键词: 妊娠并发症, 结核, 抗多种药物性/药物疗法

Abstract: Treatment of MDR-TB during pregnancy has long been regarded as a clinical difficulty, currently there is no uniform chemical regimen as a standard. In a hope to provide some relevant references for the treatment of multidrug-resistant tuberculosis (MDR-TB) during pregnancy, the author makes a systematic review regarding the progress in research of the epidemiology, anti-MDR-TB drugs and reported chemical regimens of MDR-TB during pregnancy in recent years.

Key words: Pregnancy complications, Tuberculosis, multidrug-resistant/drug therapy

韩丹，段琼红，陈梓，周美兰，陆兰英，阮汉利. 妊娠耐多药结核病化学治疗进展[J]. 中国防痨杂志, 2014, 36(2): 126-130. doi: 10.3969/j.issn.1000-6621.2014.02.009

HAN Dan, DUAN Qiong-hong, CHEN Zi, ZHOU Mei-lan, LU Lan-ying, RUAN Han-li. Progress in chemotherapy of MDR-TB during pregnancy[J]. Chinese Journal of Antituberculosis, 2014, 36(2): 126-130. doi: 10.3969/j.issn.1000-6621.2014.02.009

参考文献

［1］World Health Organization. Global Tuberculosis Report 2012. Geneva：World Health Organization, 2012.
［2］World Health Organization. The global plan to stop TB 2011—2015: transforming the fight towards elimination of tuberculosis. Geneva: World Health Organization, 2010: 1-100.
［3］Knight M, Kurinczuk JJ, Nelson-Piercy C, et al. Tuberculosis in pregnancy in the UK. BJOG, 2009, 116（4）: 584-588.
［4］Cheung JY, Shim SS, Kim Y. Infectious respiratory diseases in pregnancy-results of a 15-year study in Seoul. Clin Exp Obstet Gynecol, 2011, 38（4）: 351-354.
［5］张杏怡.妊娠合并结核病的化学治疗.医药导报, 2000, 19（1）: 17.
［6］王黎霞.中国耐多药结核病的控制亟待加强.中华结核和呼吸杂志, 2009，32（8）: 561-563.
［7］戴钟英.妊娠期用药FDA五级分类法.中国实用妇科与产科杂志，2004，20（6）：377-378.
［8］World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva：World Health Organization, 2011.
［9］Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med, 2003, 167（4）: 603-662.
［10］Francis J. Curry National Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis:a survival guide for clinicians. 2nd. California: Francis J. Curry National Tuberculosis Center and California Department of Public Health,2011:108-109.
［11］Shin S, Guerra D, Rich M, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: a report of 7 cases. Clin Infect Dis, 2003, 36(8): 996-1003.
［12］Lessnau KD, Qarah S. Multidrug-resistant tuberculosis in pregnancy: case report and review of the literature. Chest, 2003, 123(3): 953-956.
［13］Drobac PC, del Castillo H, Sweetland A, et al. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis, 2005, 40(11): 1689-1692.
［14］Palacios E, Dallman R, Munoz M, et al. Drug-resistant tuberculosis and pregnancy: treatment outcomes of 38 cases in Lima, Peru. Clin Infect Dis, 2009, 48(10): 1413-1419.
［15］World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis energency update 2008. Geneva：World Health Organization, 2008.
［16］Loebstein R,Addis A,Ho E,et al.Pregnancy outcome following gestational exposure to fluoroquinolones：a multicenter prospective controlled study. Antimicrob Agents Chemother, 1998,42(6):1336-1339.
［17］Potworowski M, Sianozecka E, Szufladowicz R. Ethionamide treatment and pregnancy.Pol Med J,1966,5(5):1152-1158.
［18］Nitta AT, Milligan D. Management of four pregnant women with multidrug-resistant tuberculosis. Clin Infect Dis, 1999, 28(6): 1298-1304.
［19］Rodríguez G, Pinto R, López F, et al. Persistent type 2 lepra reaction (erythema nodosum) and clofazimine-induced lethal enteropathy. Biomedica, 2009, 29(1): 18-24.
［20］Ryo E, Ikeya M, Sugimoto M. Clinical study of the effectiveness of imipenem/cilastatin sodium as the antibiotics of first choice in the expectant management of patients with preterm premature rupture of membranes. J Infect Chemother, 2005, 11(1): 32-36.
［21］Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. Am J Perinatol, 1998, 15(9): 523-525.
［22］Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiol Drug Saf, 2000, 9(7): 549-556.
［23］Marcus JC.Non-teratogenicity of antituberculous drugs. S Afr Med J,1967, 41(30):758-759.
［24］韩丹，陈志飞，刘妍丽，等.抗结核治疗对中晚期妊娠结核病患者的婴幼儿生长发育影响.中国防痨杂志，2013,35(5)：371-374.
［25］Brost BC, Newman RB. The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am, 1997,24(3):659-673.
［26］马玙，朱莉贞，潘毓萱.结核病.北京：人民卫生出版社，2006:90-91.
［27］Lewit T, Nebel L, Terracina S, et al. Ethambutol in pregnancy: observations on embryogenesis. Chest, 1974,66(1):25-26.
［28］Snider DE Jr, Layde PM, Johnson MW, et al. Treatment of tuberculosis during pregnancy. Am Rev Respir Dis,1980,122(1):65-79.
［29］Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 2012, 380(9846):986-993.
［30］Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23): 2397-2405.
［31］Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med, 2012, 366(23): 2151-2160.
［32］Nesri Padayatchi. Linezolid pharmacokinetics(PK) in multi-Drug resistant (MDR)/extensively-drug resistant (XDR) tuberculosis (TB) (S30PK) ［R/OL］. Pietermaritzburg:MBChB University of KwaZulu,2012(2012-08-15)［2013-06-09］.http://www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/index.html.
［33］Mercieri M, Di Rosa R, Pantosti A, et al. Critical pneumonia complicating early-stage pregnancy. Anesth Analg, 2010, 110(3): 852-854.
［34］中国防痨协会临床专业委员会.孕妇应用抗结核药物的注意事项（试行）. 中国防痨杂志,1993,15(2):82.
［35］Gach O, Corhay JL, Lousberg L, et al. Breast abscess and pregnancy toxemia revealing multidrug resistant tuberculosis. Rev Mal Respir, 1999, 16（5）: 842-845.
［36］中国全球基金结核病项目办公室. 中国全球基金结核病项目（一期）实施细则. 北京：中国全球基金结核病项目办公室，2012：45.
［37］Takashima T, Danno K, Tamura Y, et al. Treatment outcome of patients with multidrug-resistant pulmonary tuberculosis during pregnancy. Kekkaku, 2006, 81（6）: 413-418.
［38］Tabarsi P, Baghaei P, Mirsaeidi M, et al. Multi-drug resistant tuberculosis in pregnancy: need for more intensive treatment. Infection, 2007, 35（6）: 477-478.
［39］Tabarsi P, Moradi A, Baghaei P, et al. Standardised second-line treatment of multidrug-resistant tuberculosis during pregnancy. Int J Tuberc Lung Dis, 2011, 15（4）: 547-550.

[1]	夏露, 卢水华, 李涛, 刘旭晖, 刘平, 席秀红. 19例先天性结核病患儿临床特征分析并文献复习[J]. 中国防痨杂志, 2020, 42(8): 854-857.
[2]	刘琳. 35例妊娠期结核性胸膜炎患者临床诊疗结果分析[J]. 中国防痨杂志, 2020, 42(7): 731-736.
[3]	陈燕琴,. 69例妊娠并发肺结核患者的临床治疗[J]. 中国防痨杂志, 2018, 40(12): 1313-1318.
[4]	韩丹陈志飞刘妍丽梁军段琼红阮汉利. 抗结核治疗对中晚期妊娠结核病患者的婴幼儿生长发育影响[J]. 中国防痨杂志, 2013, 35(5): 361-364.
[5]	李莉,贺伟. 24例妊娠合并肺结核临床及影像特点[J]. 中国防痨杂志, 2009, 31(12): 697-700.

妊娠耐多药结核病化学治疗进展

Progress in chemotherapy of MDR-TB during pregnancy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

友情链接